The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications

• Published in: Pathology oncology research Vol. 24; no. 4; pp. 807 - 813
• Main Authors: Guo, Pingping, Chen, Wenqi, Li, Huiyu, Li, Meiying, Li, Lisha
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.10.2018; Springer Nature B.V
• Subjects: Acetylation; Acetylation - drug effects; Biomarkers, Tumor - analysis; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cancer Research; Chromatin; Female; Histone acetyltransferase; Histone deacetylase; Histone Deacetylase Inhibitors - pharmacology; Histones - metabolism; Humans; Immunology; Inhibitors; Male; Molecular chains; Molecular modelling; Oncology; Pathology; Review Paper; Therapy; Breast cancer; Histone acetylation; Histone deacetylation
• ISSN: 1219-4956; 1532-2807
• DOI: 10.1007/s12253-018-0433-5

The histone acetylation modifications (HAMs) influence a large number of cellular functions. They are mediated through histone acetyltransferase (HAT) and histone deacetylase (HDAC). Nowadays, people have realized that HAMs are crucial for development and prognosis of breast cancer. Investigations about abnormal HAMs in breast cancer focus on initiating molecular mechanisms in breast cancer development, identification of new biomarkers to predict breast cancer aggressiveness and the therapeutic potential. As HAMs are reversible, breast cancer may be treated by restoring HAMs to normal levels. Indeed, some HDAC inhibitors have been approved by the US Food and Drug Administration to treat certain cancers. Furthermore, HAT inhibitors, HAT activators and HDAC activators may also be used as drugs to treat breast cancer.